ヒト凝固因子VIIIの世界市場2020-2026:組換え第VIII因子、血漿由来第VIII因子

QYResearchが発行した調査報告書(QYR20AP01053)
◆英語タイトル:Global Human Coagulation Factor VIII Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP01053
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:117
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、ヒト凝固因子VIIIの世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、ヒト凝固因子VIIIのグローバル市場動向、メーカー別競争状況、種類別市場規模(組換え第VIII因子、血漿由来第VIII因子)、用途別市場規模(血友病A、自発性/外傷、外科、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・ヒト凝固因子VIIIの種類別市場2015-2026:組換え第VIII因子、血漿由来第VIII因子
・ヒト凝固因子VIIIの用途別市場2015-2026:血友病A、自発性/外傷、外科、その他
・ヒト凝固因子VIIIの北米市場分析
・ヒト凝固因子VIIIのアジア市場分析
・ヒト凝固因子VIIIの中南米市場分析
・ヒト凝固因子VIIIの中東・アフリカ市場分析
・関連企業情報:Shire (Baxter)、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.

The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.

Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.

Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.

Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.
In 2019, the global Human Coagulation Factor VIII market size was US$ 7911 million and is forecast to US$ 9752.2 million in 2026, growing at a CAGR of 3.0% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Human Coagulation Factor VIII.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Human Coagulation Factor VIII market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Human Coagulation Factor VIII market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Human Coagulation Factor VIII market. Readers of the report can become informed about current and future trends of the global Human Coagulation Factor VIII market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Human Coagulation Factor VIII markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Human Coagulation Factor VIII market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Human Coagulation Factor VIII market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Human Coagulation Factor VIII market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Human Coagulation Factor VIII market is segmented into
Recombinant Factor VIII
Plasma-derived Factor VIII

Market Segment by Application, the Human Coagulation Factor VIII market is segmented into
Hemophilia A
Spontanous / Trauma
Surgical
Other

This report includes the following manufacturers; we can also add the other companies as you want.
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS

The study objectives are:
To analyze and research the global Human Coagulation Factor VIII status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Human Coagulation Factor VIII manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Human Coagulation Factor VIII are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Human Coagulation Factor VIII Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Human Coagulation Factor VIII Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Recombinant Factor VIII
1.3.3 Plasma-derived Factor VIII
1.4 Market Segment by Application
1.4.1 Global Human Coagulation Factor VIII Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hemophilia A
1.4.3 Spontanous / Trauma
1.4.4 Surgical
1.4.5 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Human Coagulation Factor VIII Revenue (2015-2026)
2.1.1 Global Human Coagulation Factor VIII Revenue (2015-2026)
2.1.2 Global Human Coagulation Factor VIII Sales (2015-2026)
2.2 Human Coagulation Factor VIII Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Human Coagulation Factor VIII Sales by Regions (2015-2020)
2.2.2 Global Human Coagulation Factor VIII Revenue by Regions (2015-2020)
2.3 Global Top Human Coagulation Factor VIII Regions (Countries) Ranking by Market Size
2.4 Human Coagulation Factor VIII Industry Trends
2.4.1 Human Coagulation Factor VIII Market Top Trends
2.4.2 Market Drivers
2.4.3 Human Coagulation Factor VIII Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Human Coagulation Factor VIII Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Human Coagulation Factor VIII Manufacturers by Sales (2015-2020)
3.1.1 Global Human Coagulation Factor VIII Sales by Manufacturers (2015-2020)
3.1.2 Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Human Coagulation Factor VIII Sales in 2019
3.2 Global Top Manufacturers Human Coagulation Factor VIII by Revenue
3.2.1 Global Human Coagulation Factor VIII Revenue by Manufacturers (2015-2020)
3.2.2 Global Human Coagulation Factor VIII Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Human Coagulation Factor VIII Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Coagulation Factor VIII as of 2019)
3.4 Global Human Coagulation Factor VIII Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Human Coagulation Factor VIII Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Human Coagulation Factor VIII Market
3.7 Key Manufacturers Human Coagulation Factor VIII Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Human Coagulation Factor VIII Historic Market Review by Type (2015-2020)
4.1.2 Global Human Coagulation Factor VIII Sales Market Share by Type (2015-2020)
4.1.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2015-2020)
4.1.4 Human Coagulation Factor VIII Price by Type (2015-2020)
4.1 Global Human Coagulation Factor VIII Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Human Coagulation Factor VIII Sales Forecast by Type (2021-2026)
4.2.3 Global Human Coagulation Factor VIII Revenue Forecast by Type (2021-2026)
4.2.4 Human Coagulation Factor VIII Price Forecast by Type (2021-2026)

5 Global Human Coagulation Factor VIII Market Size by Application
5.1 Global Human Coagulation Factor VIII Historic Market Review by Application (2015-2020)
5.1.2 Global Human Coagulation Factor VIII Sales Market Share by Application (2015-2020)
5.1.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2015-2020)
5.1.4 Human Coagulation Factor VIII Price by Application (2015-2020)
5.2 Global Human Coagulation Factor VIII Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Human Coagulation Factor VIII Sales Forecast by Application (2021-2026)
5.2.3 Global Human Coagulation Factor VIII Revenue Forecast by Application (2021-2026)
5.2.4 Human Coagulation Factor VIII Price Forecast by Application (2021-2026)

6 North America
6.1 North America Human Coagulation Factor VIII Breakdown Data by Company
6.2 North America Human Coagulation Factor VIII Breakdown Data by Type
6.3 North America Human Coagulation Factor VIII Breakdown Data by Application
6.4 North America Human Coagulation Factor VIII Breakdown Data by Countries
6.4.1 North America Human Coagulation Factor VIII Sales by Countries
6.4.2 North America Human Coagulation Factor VIII Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Human Coagulation Factor VIII Breakdown Data by Company
7.2 Europe Human Coagulation Factor VIII Breakdown Data by Type
7.3 Europe Human Coagulation Factor VIII Breakdown Data by Application
7.4 Europe Human Coagulation Factor VIII Breakdown Data by Countries
7.4.1 Europe Human Coagulation Factor VIII Sales by Countries
7.4.2 Europe Human Coagulation Factor VIII Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Company
8.2 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Type
8.3 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Application
8.4 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Regions
8.4.1 Asia Pacific Human Coagulation Factor VIII Sales by Regions
8.4.2 Asia Pacific Human Coagulation Factor VIII Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Human Coagulation Factor VIII Breakdown Data by Company
9.2 Latin America Human Coagulation Factor VIII Breakdown Data by Type
9.3 Latin America Human Coagulation Factor VIII Breakdown Data by Application
9.4 Latin America Human Coagulation Factor VIII Breakdown Data by Countries
9.4.1 Latin America Human Coagulation Factor VIII Sales by Countries
9.4.2 Latin America Human Coagulation Factor VIII Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Type
10.2 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Application
10.3 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Countries
10.3.1 Middle East and Africa Human Coagulation Factor VIII Sales by Countries
10.3.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Shire (Baxter)
11.1.1 Shire (Baxter) Corporation Information
11.1.2 Shire (Baxter) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Shire (Baxter) Human Coagulation Factor VIII Products and Services
11.1.5 Shire (Baxter) SWOT Analysis
11.1.6 Shire (Baxter) Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Bayer Human Coagulation Factor VIII Products and Services
11.2.5 Bayer SWOT Analysis
11.2.6 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Corporation Information
11.3.2 CSL Business Overview and Total Revenue (2019 VS 2018)
11.3.3 CSL Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 CSL Human Coagulation Factor VIII Products and Services
11.3.5 CSL SWOT Analysis
11.3.6 CSL Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Pfizer Human Coagulation Factor VIII Products and Services
11.4.5 Pfizer SWOT Analysis
11.4.6 Pfizer Recent Developments
11.5 Grifols
11.5.1 Grifols Corporation Information
11.5.2 Grifols Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Grifols Human Coagulation Factor VIII Products and Services
11.5.5 Grifols SWOT Analysis
11.5.6 Grifols Recent Developments
11.6 Biogen
11.6.1 Biogen Corporation Information
11.6.2 Biogen Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Biogen Human Coagulation Factor VIII Products and Services
11.6.5 Biogen SWOT Analysis
11.6.6 Biogen Recent Developments
11.7 Octapharma
11.7.1 Octapharma Corporation Information
11.7.2 Octapharma Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Octapharma Human Coagulation Factor VIII Products and Services
11.7.5 Octapharma SWOT Analysis
11.7.6 Octapharma Recent Developments
11.8 NovoNordisk
11.8.1 NovoNordisk Corporation Information
11.8.2 NovoNordisk Business Overview and Total Revenue (2019 VS 2018)
11.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 NovoNordisk Human Coagulation Factor VIII Products and Services
11.8.5 NovoNordisk SWOT Analysis
11.8.6 NovoNordisk Recent Developments
11.9 Greencross
11.9.1 Greencross Corporation Information
11.9.2 Greencross Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Greencross Human Coagulation Factor VIII Products and Services
11.9.5 Greencross SWOT Analysis
11.9.6 Greencross Recent Developments
11.10 Kedrion
11.10.1 Kedrion Corporation Information
11.10.2 Kedrion Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Kedrion Human Coagulation Factor VIII Products and Services
11.10.5 Kedrion SWOT Analysis
11.10.6 Kedrion Recent Developments
11.11 BPL
11.11.1 BPL Corporation Information
11.11.2 BPL Business Overview and Total Revenue (2019 VS 2018)
11.11.3 BPL Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 BPL Human Coagulation Factor VIII Products and Services
11.11.5 BPL SWOT Analysis
11.11.6 BPL Recent Developments
11.12 Hualan Bio
11.12.1 Hualan Bio Corporation Information
11.12.2 Hualan Bio Business Overview and Total Revenue (2019 VS 2018)
11.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 Hualan Bio Human Coagulation Factor VIII Products and Services
11.12.5 Hualan Bio SWOT Analysis
11.12.6 Hualan Bio Recent Developments
11.13 RAAS
11.13.1 RAAS Corporation Information
11.13.2 RAAS Business Overview and Total Revenue (2019 VS 2018)
11.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 RAAS Human Coagulation Factor VIII Products and Services
11.13.5 RAAS SWOT Analysis
11.13.6 RAAS Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Human Coagulation Factor VIII Sales Channels
12.2.2 Human Coagulation Factor VIII Distributors
12.3 Human Coagulation Factor VIII Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.1.1 Global Human Coagulation Factor VIII Sales Forecast by Regions (2021-2026)
13.1.2 Global Human Coagulation Factor VIII Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.2.2 North America Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.2.3 North America Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.3.2 Europe Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.3.3 Europe Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.4.2 Asia Pacific Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Human Coagulation Factor VIII Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.5.2 Latin America Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.5.3 Latin America Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Human Coagulation Factor VIII Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Shire (Baxter)、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ヒト凝固因子VIIIの世界市場2020-2026:組換え第VIII因子、血漿由来第VIII因子(Global Human Coagulation Factor VIII Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。